Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepine

References

• Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW,Goldstein JA. 2001. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825–831.
   PubMed Web of Science ®Google Scholar
• Ekroos M, Sjögren T. 2006. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103:13682–13687.
   PubMed Web of Science ®Google Scholar
• Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. 2004. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100.
   PubMedGoogle Scholar
• Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. 1996. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940–947.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 1999. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Miller GP, Guengerich FP. 2000. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929–5939.
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L. 2001. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–779.
   PubMedGoogle Scholar
• Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969–1979.
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Domanski TL, Halpert JR. 2002. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495–506.
   PubMed Web of Science ®Google Scholar
• Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, Tracy TS. 1998. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137–4147.
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. 2002. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121–132.
   PubMedGoogle Scholar
• Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA. 2005. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 313:302–309.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee SS, Jeong HE, Shon JH, Ryu JY, Sunwoo YE, Liu KH, Kang W, Park YJ, Shin CM, Shin JG. 2007. The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos 35:2095–2101.
   PubMedGoogle Scholar
• Murayama N, Nakamura T, Saeki M, Soyama A, Saito Y, Sai K, Ishida S, Nakajima O, Itoda M, Ohno Y, Ozawa S, Sawada J. 2002. CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet 17:150–156.
   Google Scholar
• Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, Ozawa S, Aoyagi N, Kamatani N, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Yoshida T, Minami H, Saijo N, Katori N, Sawada J. 2006. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 80:179–191.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Torimoto N, Ishii I, Ariyoshi N, Nakasa H, Ohmori S, Kitada M. 2003. CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos 31:432–438.
   PubMed Web of Science ®Google Scholar
• Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378.
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD. 2000. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–388.
   PubMedGoogle Scholar
• Phillips AH, Langdon RG. 1962. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 237:2652–2660.
   PubMed Web of Science ®Google Scholar
• Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. 2008. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 62:529–537.
   PubMed Web of Science ®Google Scholar
• Saito Y, Maekawa K, Ozawa S, Sawada J. 2007. Genetic polymorphisms and haplotypes of major drug metabolizing enzymes in Asians and their comparison with other ethnic populations. Curr Pharmacogenomics 5:49–78.
   Google Scholar
• Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. 2000. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48–56.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
   PubMed Web of Science ®Google Scholar
• Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin CC, Singh R, Wong BK, Yergey JA, Lin JH, Pearson PG, Baillie TA, Rodrigues AD, Rushmore TH. 2001. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17–36.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389–430.
   PubMed Web of Science ®Google Scholar
• Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H. 2004. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683–686.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanaka H, Okumura K, Yasuhara M, Hori R. 1986. An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers. J Pharmacobiodyn 9:161–173.
   Google Scholar
• Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N,Gillam EM, Guengerich FP, Shimada T, Yokoi T. 1999. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. Drug Metab Dispos 27:999–1004.
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. 2004. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-å resolution. J Biol Chem 279:38091–38094.
   PubMed Web of Science ®Google Scholar
• Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Horio T, Takiuchi S, Kawano Y, Minematsu K, Naritomi H, Tomoike H, Sawada J, Miyata T. 2008. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549–1557.
   PubMed Web of Science ®Google Scholar